NicOx SA announced that the Joint Advisory Committees of the US Food and Drug Administration (FDA), including the Arthritis Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, voted by 16 to one with one abstention that they did not have sufficient evidence at this time to support the approval of naproxcinod for the relief of the signs and symptoms of ...